AR052498A1 - Vacuna - Google Patents

Vacuna

Info

Publication number
AR052498A1
AR052498A1 ARP060100773A ARP060100773A AR052498A1 AR 052498 A1 AR052498 A1 AR 052498A1 AR P060100773 A ARP060100773 A AR P060100773A AR P060100773 A ARP060100773 A AR P060100773A AR 052498 A1 AR052498 A1 AR 052498A1
Authority
AR
Argentina
Prior art keywords
vzv
adjuvant
vaccine
postherpeptic
mpl
Prior art date
Application number
ARP060100773A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052498(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of AR052498A1 publication Critical patent/AR052498A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Uso de una composicion inmunogena que comprende gE de VZV, o uno de sus fragmentos inmunogenos, y un adyuvante TH-1 en la preparacion de un medicamento para la prevencion o alivio de herpes zoster y/o neuralgia postherpéptica. También se reivindican composiciones que comprenden un antígeno gE de VZV truncado y un adyuvante que contiene QS21, colesterol y 3D MPL.
ARP060100773A 2005-03-03 2006-03-01 Vacuna AR052498A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine

Publications (1)

Publication Number Publication Date
AR052498A1 true AR052498A1 (es) 2007-03-21

Family

ID=34430592

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP060100773A AR052498A1 (es) 2005-03-03 2006-03-01 Vacuna
ARP170100008A AR107285A2 (es) 2005-03-03 2017-01-03 Vacuna

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170100008A AR107285A2 (es) 2005-03-03 2017-01-03 Vacuna

Country Status (35)

Country Link
US (3) US20080171079A1 (es)
EP (4) EP2281831B1 (es)
JP (2) JP5420842B2 (es)
KR (2) KR101357204B1 (es)
CN (2) CN101189254B (es)
AR (2) AR052498A1 (es)
AU (1) AU2006222225B2 (es)
BR (1) BRPI0607840B1 (es)
CA (2) CA2882255C (es)
CY (5) CY1116108T1 (es)
DK (4) DK2281830T3 (es)
EA (1) EA011884B1 (es)
ES (4) ES2532803T3 (es)
GB (1) GB0504436D0 (es)
HK (1) HK1111427A1 (es)
HR (4) HRP20150142T1 (es)
HU (4) HUE032544T2 (es)
IL (1) IL185442A (es)
LT (4) LT2281831T (es)
LU (1) LUC00087I2 (es)
MA (1) MA29714B1 (es)
MX (2) MX2007010626A (es)
MY (1) MY148464A (es)
NL (1) NL300951I2 (es)
NO (1) NO341841B1 (es)
NZ (1) NZ561075A (es)
PE (2) PE20061287A1 (es)
PL (4) PL2281830T3 (es)
PT (4) PT2301955T (es)
SI (4) SI2281831T1 (es)
TR (2) TR201809393T4 (es)
TW (1) TWI403517B (es)
UA (1) UA94900C2 (es)
WO (1) WO2006094756A2 (es)
ZA (1) ZA200707144B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
RU2010105858A (ru) * 2007-07-19 2011-08-27 Новавакс, Инк. (Us) Вирусоподобные частицы (vlp) вируса varicella zoster и антигены
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
RS63983B1 (sr) 2010-08-31 2023-03-31 Glaxosmithkline Biologicals Sa Pegilovani lipozomi za isporuku rnk koja kodira imunogen
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
TW201601750A (zh) * 2013-10-03 2016-01-16 Nitto Denko Corp 注射疫苗組合物
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
CN107106675A (zh) * 2014-12-18 2017-08-29 葛兰素史密丝克莱恩生物有限公司 疫苗接种
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
EP4349404A3 (en) 2015-10-22 2024-06-19 ModernaTX, Inc. Respiratory virus vaccines
EA201891001A1 (ru) * 2015-10-22 2018-11-30 МОДЕРНАТиЭкс, ИНК. Вакцины на основе нуклеиновых кислот против вируса ветряной оспы (vzv)
SG11201803594TA (en) 2015-11-06 2018-05-30 Adjuvance Technologies Inc Triterpene saponin analogues
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
KR102028463B1 (ko) * 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3560512A4 (en) * 2016-12-26 2020-07-22 Mogam Institute for Biomedical Research COMPOSITION OF VACCINE AGAINST ZONA
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
SG11201909584QA (en) * 2017-04-25 2019-11-28 Adjuvance Technologies Inc Triterpene saponin analogues
JP7177082B2 (ja) * 2017-04-25 2022-11-22 アジュバンス・テクノロジーズ・インコーポレーテッド トリテルペンサポニン類似物
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
IE87414B1 (en) 2017-05-30 2023-07-19 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
CA3075822A1 (en) 2017-10-16 2019-04-25 Adjuvance Technologies, Inc. Triterpene saponin analogues
BR112020010790A2 (pt) 2017-12-01 2020-11-10 Glaxosmithkline Biologicals S.A. purificação da saponina
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
US11642408B2 (en) * 2018-05-23 2023-05-09 Mogam Institute For Biomedical Research Antigen variant of Varicella Zoster virus and use thereof
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
CN113164586B (zh) * 2018-09-27 2024-04-16 武汉博沃生物科技有限公司 免疫组合物及其制备方法与应用
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
JP2022535091A (ja) 2019-06-05 2022-08-04 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
WO2021115410A1 (zh) * 2019-12-13 2021-06-17 南京远大赛威信生物医药有限公司 免疫刺激组合物及其用途
US20230110839A1 (en) * 2020-02-28 2023-04-13 Celltrion Inc. Varicella zoster virus fusion protein and immunogenic composition comprising same
US20230287038A1 (en) 2020-08-07 2023-09-14 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
KR102660479B1 (ko) * 2020-09-11 2024-04-25 주식회사 유바이오로직스 수두 또는 대상포진 백신 조성물 및 이를 이용하는 방법
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
AU2022397292A1 (en) 2021-11-24 2024-05-30 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116350770B (zh) * 2021-12-28 2024-07-12 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (es) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69017769T2 (de) 1989-06-27 1995-07-13 Smithkline Beecham Biologicals S.A., Rixensart Verbindungen.
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
ZA929870B (en) 1991-12-23 1993-08-18 Duphar Int Res Adjuvants
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
CA2139515C (en) * 1992-07-17 2008-12-23 Gary B. Calandra Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
DK0817847T4 (da) * 1995-03-23 2009-10-05 Immunex Corp IL-17-receptor
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
PL190237B1 (pl) 1997-04-01 2005-11-30 Corixa Corp Kompozycja adiuwantowa, szczepionka, sposób wytwarzania kompozycji adiuwantowej oraz zastosowanie
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
JP2004511527A (ja) * 2000-10-18 2004-04-15 グラクソスミスクライン　バイオロジカルズ　ソシエテ　アノニム ワクチン
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
HUE038467T2 (hu) 2018-10-29
MA29714B1 (fr) 2008-09-01
BRPI0607840B1 (pt) 2021-06-29
AU2006222225B2 (en) 2012-08-16
PE20100658A1 (es) 2010-10-23
PE20061287A1 (es) 2006-12-07
EA011884B1 (ru) 2009-06-30
CY1116108T1 (el) 2017-02-08
NZ561075A (en) 2009-06-26
EP2301955A3 (en) 2011-11-16
EP2281831A3 (en) 2011-11-16
NO341841B1 (no) 2018-02-05
US20110045059A1 (en) 2011-02-24
MX2007010626A (es) 2007-10-16
US20110104260A1 (en) 2011-05-05
LT2281831T (lt) 2018-07-10
US7939084B1 (en) 2011-05-10
KR20070110413A (ko) 2007-11-16
WO2006094756A3 (en) 2007-02-15
TR201809393T4 (tr) 2018-07-23
EP1858917B1 (en) 2014-12-24
PL2301955T3 (pl) 2018-08-31
JP2008531637A (ja) 2008-08-14
EP2281831B1 (en) 2018-04-18
PL2281830T3 (pl) 2017-06-30
ES2532803T3 (es) 2015-03-31
CA2600905A1 (en) 2006-09-14
SI2281831T1 (en) 2018-07-31
HRP20180989T1 (hr) 2018-08-10
EP2281831A2 (en) 2011-02-09
HK1111427A1 (en) 2008-08-08
HRP20150142T1 (hr) 2015-05-22
CY1118629T1 (el) 2017-07-12
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
PT2281830T (pt) 2017-02-24
CA2882255C (en) 2018-03-27
PT1858917E (pt) 2015-02-24
LT2281830T (lt) 2017-02-10
CN101189254A (zh) 2008-05-28
DK2281831T3 (en) 2018-06-14
CN101189254B (zh) 2013-05-22
TWI403517B (zh) 2013-08-01
HUS1800038I1 (hu) 2018-10-29
EP2281830B1 (en) 2016-12-21
KR20140006115A (ko) 2014-01-15
ES2618037T3 (es) 2017-06-20
CY1121211T1 (el) 2020-05-29
HRP20180988T1 (hr) 2018-08-10
KR101357204B1 (ko) 2014-02-06
AR107285A2 (es) 2018-04-18
PL1858917T3 (pl) 2015-05-29
AU2006222225A1 (en) 2006-09-14
ZA200707144B (en) 2009-11-25
EP2301955A2 (en) 2011-03-30
BRPI0607840A2 (pt) 2009-06-13
EP2281830A2 (en) 2011-02-09
LT2301955T (lt) 2018-07-10
ES2675055T3 (es) 2018-07-06
SI1858917T1 (sl) 2015-03-31
US20080171079A1 (en) 2008-07-17
PL2281831T3 (pl) 2018-08-31
NL300951I1 (nl) 2018-09-26
HRP20170081T1 (hr) 2017-03-24
JP5420842B2 (ja) 2014-02-19
TW200643028A (en) 2006-12-16
IL185442A0 (en) 2008-01-06
LUC00087I2 (es) 2018-11-26
CY2018025I1 (el) 2018-12-12
PT2301955T (pt) 2018-06-18
DK2301955T3 (en) 2018-06-14
ES2675054T3 (es) 2018-07-06
NL300951I2 (nl) 2020-08-31
EP2281830A3 (en) 2012-01-25
WO2006094756A2 (en) 2006-09-14
SI2301955T1 (en) 2018-07-31
CN103028113B (zh) 2015-05-20
JP2013144710A (ja) 2013-07-25
HUE032544T2 (en) 2017-10-30
SI2281830T1 (sl) 2017-03-31
EP2301955B1 (en) 2018-04-18
EP1858917A2 (en) 2007-11-28
EA200701632A1 (ru) 2008-02-28
LTC2281831I2 (lt) 2020-08-25
DK1858917T3 (da) 2015-02-02
HUE038468T2 (hu) 2018-10-29
CY1120347T1 (el) 2018-12-12
CA2882255A1 (en) 2006-09-14
EP1858917B8 (en) 2015-05-06
DK2281830T3 (en) 2017-03-20
PT2281831T (pt) 2018-06-15
IL185442A (en) 2013-07-31
GB0504436D0 (en) 2005-04-06
MX346865B (es) 2017-04-04
CA2600905C (en) 2015-05-05
JP5840167B2 (ja) 2016-01-06
CN103028113A (zh) 2013-04-10
MY148464A (en) 2013-04-30
NO20074392L (no) 2007-11-27
CY2018025I2 (el) 2018-12-12
LTPA2018012I1 (lt) 2018-11-12

Similar Documents

Publication Publication Date Title
AR052498A1 (es) Vacuna
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
BRPI1013780B8 (pt) Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
CU23759A3 (es) Composiciones inmunogénicas
AR040204A1 (es) Composicion de vacuna meningococica multivalente
AR054251A1 (es) Vacuna de toxoide de c. perfringens alfa
AR058753A1 (es) Uso de composiciones nutricionales con fosfolipidos esfingolipidos y colesterol
SE0301998D0 (sv) Quil A fraction with low toxicity and use thereof
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
ES2422556T3 (es) Tratamiento de hepatitis vírica
AR059203A1 (es) Composiciones para uso vaginal
UY30948A1 (es) Uso, en composicion de ligante hidraulico, de carbonato de calcio molido en seco con copolimero del acido (met) acrilico + funcion alcoxi / hidroxi polialquilenglicol
AR108718A2 (es) Composición
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
ECSP10010661A (es) Dronedarona para la prevención de la cardioversión
AR063460A1 (es) Composicion solida para el tratamiento de agua
GB0703976D0 (en) Liposome preparation
CL2008002485A1 (es) Uso de gestagenos en combinacion con (6s)-5-metiltetrahidrofolato para el tratamiento de la endometriosis con reduccion de los efectos colaterales terapeuticos; procedimiento de preparacion de una composicion farmaceutica que comprende a dichos compuestos.
CL2008001102A1 (es) Compuestos derivados de [1,2,3]triazolo [4,5-b]piridina-carboxamidas, inhibidores de monoacilglicerol lipasa (mgl); procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros.
NZ611463A (en) Inactivated dengue virus vaccine with aluminium-free adjuvant

Legal Events

Date Code Title Description
FC Refusal